Completed PHASE3 INTERVENTIONAL 2-arm NCT00335283

Efficacy of Lansoprazole in Chronic Post Nasal Drip (PND)

Randomized Placebo-Controlled Trial of BID Lansoprazole in Isolated Chronic Post Nasal Drip

Sponsor: TAP Pharmaceutical Products Inc.

Interventions Lansoprazole Tablet PH and impedence testing lansoprazole manometry placebo

Updated 9 times since 2017 Last updated: Jul 17, 2012 Started: Aug 31, 2006 Primary completion: Dec 31, 2008 Completion: Dec 31, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Larynx Disease and is currently completed. TAP Pharmaceutical Products Inc. leads this study, which shows 9 recorded versions since 2006 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE3
Dec 2021 — Dec 2022 [monthly]

Completed PHASE3

▶ Show 4 earlier versions

Jan 2021 — Dec 2021 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Feb 2017 — Jun 2018 [monthly]

Completed PHASE3
Jan 2017 — Feb 2017 [monthly]

Completed PHASE3

First recorded

Aug 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

TAP Pharmaceutical Products Inc.
Vanderbilt University

Data source: Vanderbilt University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nashville, United States